Abstract
Objectives To quantify the associations between shielding status and loneliness at the start of the COVID-19 pandemic, and physical activity (PA) levels throughout the pandemic.
Methods Demographic, health and lifestyle characteristics of 7748 cognitively healthy adults aged >50, and living in London, were surveyed from April 2020 to March 2021. The International Physical Activity Questionnaire (IPAQ) short-form assessed PA before COVID-19 restrictions, and up to 6 times over 11 months. Linear mixed models investigated associations between baseline shielding status, loneliness, and time-varying PA.
Results Participants who felt ‘often lonely’ at the outset of the pandemic completed an average of 522 and 547 fewer Metabolic Equivalent of Task (MET) minutes/week (95% CI: -809, -236, p<0.001) (95% CI: -818, -275, p<0.001) than those who felt ‘never lonely’ in univariable and multivariable models adjusted for demographic factors respectively. Those who felt ‘sometimes lonely’ completed 112 fewer MET minutes/week (95% CI: -219, -5, p=0.041) than those who felt ‘never lonely’ following adjustment for demographic factors.
Participants who were shielding at the outset of the pandemic completed an average of 352 fewer MET minutes/week than those who were not (95% CI: -432, -273; p<0.001) in univariable models and 228 fewer MET minutes/week (95% CI: -307, -150, p<0.001) following adjustment for demographic factors. No significant associations were found after further adjustment for health and lifestyle factors.
Conclusions Those shielding or lonely at pandemic onset were likely to have completed low levels of PA during the pandemic. These associations are influenced by co-morbidities and health status.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Sara Ahmadi-Abhari declares funding from EIT-health for a brain ageing PhD school programme, and is an unpaid advisor for small-sized chronic care management start-up (Medsien); Chi Udeh-Momoh declares: funding from a project grant funding consortia that included Janssen R&D, Gates Foundation, Merck and Takeda, a project grant from RoseTrees Foundation Trust and a project grant from Alzheimers Research UK; funding for a speaking engagement at the Lausanne IX workshop, an engagement at the Meeting of the Minds Neuroscience Conference, and was an invited speaker at the Reserve in Dementia Conference; is a scientific advisor at the Brain and Mind Institute, Aga Khan University, Nairobi; and is an unpaid executive committee member at Biofluids-based Biomarker Professional Interest Area for iSTAART, and a board of trustee member for the British Society for Neuroendocrinology; Lefkos T. Middleton reports research funding from Janssen, Novartis, Merck and Takeda, outside the submitted work and had unpaid leadership roles at the Clinical Trials in Alzheimers Disease (CTAD) executive committee, WW FINGERS, and the European Consortium of Alzheimers Disease; Celeste A. de Jager Loots received a 1-year research contract from the Foundations FINGERS Brain Health Institute, Sweden which contributed to her salary, and receives annual payments from the MCI and B Vitamin project from the University of Oxford, and has an unpaid advisory role membership at foodforthebrain.org; David Salman is funded by an Imperial College and National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) fellowship, and is an unpaid advisory board member for the Primary Care Rheumatology and Musculoskeletal Medicine society (PCRMM).
Funding Statement
Work towards this article was in part supported by the National Institute for Health Research (NIHR) Applied Research Collaboration Northwest London and Imperial Biomedical Research Centre (BRC). DS and TB are supported by Wellcome / NIHR BRC fellowships. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. Imperial College London is the sponsor for the CCRR study, and has no influence on the direction or content of the work. There was no external financial funding for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the Imperial College Research and Ethics Committee (ICREC) and Joint Research Compliance Office (22/04/2020; 20IC5942). All participants were required to provide informed consent before taking part in the study. Data collected as a part of this study are anonymized and kept strictly confidential in accordance with the UK General Data Protection Regulations (2016).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Transparency declaration The lead authors confirm that the submitted manuscript is an honest, accurate and transparent account of the study being reported. No important aspects of the study have been omitted.
Ethics approval This research was approved by the Imperial College Research and Ethics Committee (ICREC) and Joint Research Compliance Office (22/04/2020; 20IC5942). All participants were required to provide informed consent before taking part in the study. Data collected as a part of this study are anonymized and kept strictly confidential in accordance with the UK General Data Protection Regulations (2016).
Data sharing This is an ongoing study, but anonymised data can be provided upon request for the purposes of further data analysis, and can be requested from the Data Management Co-ordinator, Parthenia Giannakopoulou: parthenia.giannakopoulou13{at}imperial.ac.uk
Dissemination declaration Participants in the CHARIOT cohort are informed by regular newsletter of all publications pertaining to the cohort.
Funding statement Work towards this article was in part supported by the National Institute for Health Research (NIHR) Applied Research Collaboration Northwest London and Imperial Biomedical Research Centre (BRC). DS and TB are supported by Welcome / NIHR BRC fellowships. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. Imperial College London is the sponsor for the CCRR study, and has no influence on the direction or content of the work. There was no external financial funding for the study.
Patient and public involvement: Older adult volunteers (60-80 years of age) from various social and cultural backgrounds provided feedback on the survey content. This feedback was incorporated into the survey design.
Conflicts of interest All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Sara Ahmadi-Abhari declares funding from EIT-health for a brain ageing PhD school programme, and is an unpaid advisor for small-sized chronic care management start-up (Medsien); Chi Udeh-Momoh declares: funding from a project grant funding consortia that included Janssen R&D, Gates Foundation, Merck and Takeda, a project grant from RoseTrees Foundation Trust and a project grant from Alzheimers Research UK; funding for a speaking engagement at the Lausanne IX workshop, an engagement at the Meeting of the Minds Neuroscience Conference, and was an invited speaker at the Reserve in Dementia Conference; is a scientific advisor at the Brain and Mind Institute, Aga Khan University, Nairobi; and is an unpaid executive committee member at Biofluids-based Biomarker Professional Interest Area for iSTAART, and a board of trustee member for the British Society for Neuroendocrinology; Lefkos T. Middleton reports research funding from Janssen, Novartis, Merck and Takeda, outside the submitted work and had unpaid leadership roles at the Clinical Trials in Alzheimer’s Disease (CTAD) executive committee, WW FINGERS, and the European Consortium of Alzheimer’s Disease; Celeste A. de Jager Loots received a 1-year research contract from the Foundations FINGERS Brain Health Institute, Sweden which contributed to her salary, and receives annual payments from the MCI and B Vitamin project from the University of Oxford, and has an unpaid advisory role membership at foodforthebrain.org; David Salman is funded by an Imperial College and National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) fellowship, and is an unpaid advisory board member for the Primary Care Rheumatology and Musculoskeletal Medicine society (PCRMM).
Data Availability
This is an ongoing study, but anonymised data can be provided upon request for the purposes of further data analysis, and can be requested from the Data Management Co-ordinator, Parthenia Giannakopoulou: parthenia.giannakopoulou13{at}imperial.ac.uk
